Project Grant R01CA283080
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$530K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $193,797 to The Washington University's Office of Sponsored Research Services Division to conduct research aimed at defining the mechanisms underlying the regulation of natural killer (NK) cell anti-leukemia function. The three-year project, running from August 1, 2024 to July 31, 2027, will investigate the transcription factors and epigenetic changes that...
This $107,052 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to advance the understanding of tissue-resident and adaptive natural killer (NK) cell responses in cancer. The award recipient, Regents of the University of Minnesota, will use orthogonal methods to determine if a specific NK cell subtype (CD56bright "Bright-TANKS") is associated with increased recruitment of anti-tumor immune cells like dendritic cells and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $693,880 to the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) to develop a novel cancer immunotherapy approach using engineered CD4+ T cells. The goal is to overcome treatment resistance in solid tumors, such as melanoma, by engineering CD4+ T cells to express IL-12 and IL-18 to activate innate immune cells within the tumor microenvironment. The award...
This federal Project Grant award from the National Cancer Institute (under CFDA 93.395 - Cancer Treatment Research) provides $513,859 to the Dana-Farber Cancer Institute, Inc. in Boston, MA to develop a novel platform for persistent adoptive cellular therapy using hematopoietic stem cell (HSC)-derived chimeric antigen receptor (CAR)-expressing natural killer (NK) cells. The project aims to leverage naturally occurring NK-specific regulatory elements to restrict CAR expression to the NK cell...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $256,500.00 to the Fred Hutchinson Cancer Center (doing business as the Seattle Cancer Care Alliance) to conduct research on the regulation of mucosal immunity and the coordination of the NK cell response during viral infections. The research aims to improve understanding of how regulatory T cells modulate NK cell activation and function in...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $169,344 to the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) to conduct research aimed at improving adoptive cell therapy (ACT) for pancreatic cancer. The key objectives are to: 1) Identify targetable T cell-intrinsic epigenetic regulators of ACT T cell dysfunction in the tumor microenvironment, and 2) Identify targetable intra-tumor cellular...
The federal Project Grant award of $2,288,000 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Fred Hutchinson Cancer Center, doing business as the Seattle Cancer Care Alliance. The purpose of the award is to conduct research aimed at "Targeting Epidermal Plasticity to Prevent Triple Negative Breast Cancer". The research will take place in Seattle, WA over a four-year period from April 1, 2025 through March...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $132,462 to the Fred Hutchinson Cancer Center in Seattle, WA to conduct research aimed at improving engineered T cell receptor (TCR-T) cell therapy for solid tumors. The research seeks to determine why TCR-T cells form a specific stem-like reservoir in tumor-draining lymph nodes, which differs from the reservoir formed by naturally occurring tumor-specific T cells. The project will...
The federal Project Grant award for $1,339,955 from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research aimed at identifying and overcoming resistance after donor-derived ex vivo expanded natural killer (NK) cell therapy and haploidentical hematopoietic cell transplantation (haplo-HCT) in children and young adults with high-risk acute myeloid leukemia (AML). The primary awardee, the Research Institute at Nationwide Children's Hospital,...
This federal Project Grant award of $217,863 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will support research by the University of Colorado-Denver to study the role of decidual natural killer (DNK) cells and the KIR/HLA axis in melanoma tumor invasion and immune evasion. The two-year project aims to identify biomarkers that can predict risk of disease progression and response to immune checkpoint blockade (ICB) therapy for melanoma patients. The...